[Two cases of therapy-related myelodysplastic syndrome after concurrent oral cancer chemoradiotherapy].
Therapy-related myelodysplastic syndrome (t-MDS) and therapy-related leukemia (TRL) are reported increasingly often, and we report two cases of T-MDS after concurrent chemoradiotherapy (CCRT) with oral cancer. Patients underwent CCRT with cisplatin (CDDP) or carboplatin (CBDCA). The interval between primary CCRT and t-MDS was 11 months in 1 case and 14 years in the other. Chromosomal analysis indicated abnormal karyotypes. Platinum has a relatively lower t-MDS risk than alkylating agents or topoisomerase II inhibitors, but our experience supports concurrent use of radiotherapy with platinum affects the risk of t-MDS. If pancytopenia is detected after CCRT, bone marrow and cytogenetic examinations should be conducted to rule out T-MDS.
Doi
Katsuyuki
K
Department of Head and Neck Surgery, Chiba Cancer Center, Chiba.
Asano
Takanori
T
Kinoshita
Takashi
T
D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D003131:Combined Modality Therapy / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000628:therapy*; D009190:Myelodysplastic Syndromes / Q000209:etiology*; D014062:Tongue Neoplasms / Q000628:therapy